ResMed Inc
RMD: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$218.00 | Tbqbmrj | Rngvrppdl |
ResMed Faces Near-Term Headwinds, but Long-Run Strategy and Outlook Sound
Business Strategy and Outlook
ResMed is taking a “smart devices” and “big data” approach to further entrench itself as one of the two leading players in the global sleep apnea market. The strategy is two-fold – accelerating diagnosis of the underpenetrated market and monitoring patient compliance which keeps diagnosed patients in the treatment net and payers happier to reimburse the cost of respiratory devices.